SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

Andere Sprachen Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Aktien

A1J68D

CNE100001M79

2196

Verzögert Hong Kong S.E. Andere Börsenplätze 07:51:04 21.05.2024			% 5 Tage	% 1. Jan.
12,98 ^HKD	-4,14 %		-2,99 %	-23,53 %

15.05.	Fosun Pharma-Einheit Fosun Health erhält Kapitalspritze von Foshan Chanxi City Investment	MT
15.05.	China genehmigt klinische Studien für Brustkrebsmedikamente	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Fosun Pharma Unit Fosun Health to Receive Capital Injection from Foshan Chanxi City Investment	15.05.
China Approves Clinical Trials For Breast Cancer Drugs	15.05.
Fosun Pharma Unit Gets China Marketing Approval for Schizophrenia Tablets	10.05.
Shanghai Fosun Pharmaceutical Unit Secures China Nod to Sell Schizophrenia Drug	09.05.
US FDA Grants Clinical Trial Approval for Fosun Unit's Gastric Cancer Tablets	07.05.
Fosun Pharma's Q1 Profit Slumps 38%	30.04.
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	29.04.
Fosun Pharma Unit Gets Marketing Registration Approval for Tuberculosis Drug from Chinese Regulator	24.04.
China Approves Fosun Unit's Phase 2 Clinical Trial for Cancer Combination Therapy	18.04.
Fosun Pharma Unit’s New Drug Application for CMV, HSV Drug Accepted by Chinese Regulator	17.04.
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	15.04.
China Accepts New Drug Applications for Fosun Pharma's Iron Overload Syndrome Drugs	08.04.
Tranche Update on Shanghai Fosun Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on March 27, 2024.	03.04.
Telefield Medical Imaging Limited announced that it has received HKD 59.571525 million in funding Gobi Partners	31.03.
Fosun Pharma's 2023 Attributable Profit Declines, Misses Estimates	27.03.
Shanghai Fosun Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 200 million worth of its shares.	27.03.
Shanghai Fosun Pharmaceutical Co., Ltd. Proposes Final Dividend for the Year Ended 31 December 2023	26.03.
Shanghai Fosun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	26.03.
Shanghai Fosun Pharmaceutical Co., Ltd. authorizes a Buyback Plan.	26.03.
Shanghai Fosun Pharma Unit's Oral Schizophrenia Drug Gets Marketing Registration	14.03.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Hong Kong S.E.

Aktien

A1J68D

CNE100001M79

2196

Andere Sprachen

Filter